Profund Advisors LLC Boosts Holdings in Thermo Fisher Scientific Inc. $TMO

Posted by Brian Himes on May 20th, 2026

Profund Advisors LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 25.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,113 shares of the medical research company’s stock after acquiring an additional 1,236 shares during the quarter. Profund Advisors LLC’s holdings in Thermo Fisher Scientific were worth $3,542,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. High Note Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares in the last quarter. JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific during the third quarter worth approximately $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Olistico Wealth LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. Finally, Cloud Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth $31,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

TMO has been the topic of several analyst reports. Barclays decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Stifel Nicolaus decreased their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $616.10.

Get Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Up 1.4%

Shares of Thermo Fisher Scientific stock opened at $448.34 on Wednesday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The company’s fifty day simple moving average is $483.39 and its two-hundred day simple moving average is $540.37. The company has a market cap of $166.61 billion, a P/E ratio of 24.65, a PEG ratio of 1.96 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.